Gomilla v. Bracco Diagnostics, Inc.

CourtDistrict Court, E.D. Louisiana
DecidedJuly 3, 2019
Docket2:18-cv-10212
StatusUnknown

This text of Gomilla v. Bracco Diagnostics, Inc. (Gomilla v. Bracco Diagnostics, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. Louisiana primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gomilla v. Bracco Diagnostics, Inc., (E.D. La. 2019).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA

JUDY GOMILLA, CIVIL DOCKET Plaintiff

VERSUS NO. 18-10212

BRACCO DIAGNOSTICS, INC., et al SECTION: “E” (2) Defendant

ORDER AND REASONS Before the Court is a Motion to Dismiss for Failure to State a Claim filed by Defendants McKesson Corporation and McKesson Medical-Surgical, Inc. (collectively, “McKesson”),1 a Motion to Dismiss for Failure to State a Claim filed by Defendants GE Healthcare, Inc. and General Electric Company (collectively “GEHC”),2 and a Motion to Dismiss filed by Defendant Bracco Diagnostics, Inc. (“BDI”).3 Plaintiff Judy Gomilla opposes each of these motions.4 In each Opposition, Plaintiff states she will amend the Complaint if the Court deems it necessary.5 For the reasons that follow, McKesson’s, GEHC’s, and BDI’s motions to dismiss are each GRANTED IN PART, and Plaintiff is GRANTED leave to amend her complaint with respect to any remaining claims. BACKGROUND Plaintiff alleges she was administered gadolinium-based contrast agents (“GBCAs”).6 Plaintiff alleges various defendants including McKesson distributed the GBCAs administered to Plaintiff,7 and various defendants including GEHC and BDI

1 R. Doc. 30. 2 R. Doc. 33. 3 R. Doc. 35. 4 R. Docs. 36, 37, and 38. 5 Id. 6 R. Doc. 1. at ¶¶ II-V. 7 Id. at ¶ XXIII. designed, manufactured, marketed, and sold the GBCAs administered to Plaintiff.8 As a result of being injected with GBCAs, Plaintiff allegedly suffered from symptoms of Gadolinium Deposition Disease (“GDD”), including “skin patchiness, bone and joint pain and cognitive impairment.” 9 Plaintiff filed the present suit on October 31, 2018. McKesson, GEHC, and BDI have individually moved to dismiss each of Plaintiff’s claims

against them.10 LEGAL STANDARD I. Motion to Dismiss Under Rule 12(b)(6) Rule 12(b)(6) provides for dismissal of a claim if the claimant fails to set forth a factual allegation in support of its claim that would entitle it to relief (i.e. for “failure to state a claim”).11 Those factual allegations “must be enough to raise a right to relief above the speculative level.”12 “To survive a motion to dismiss, a complaint must contain sufficient factual matter, accepted as true, to ‘state a claim to relief that is plausible on its face.’”13 “A claim has facial plausibility when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.”14 The Court must accept all well-pleaded facts as true and must draw

all reasonable inferences in favor of the non-moving party,15 but the Court need not accept as true legal conclusions couched as factual allegations.16 “Motions to dismiss under Rule

8 Id. at ¶¶ III-IV. 9 Id. at ¶¶ VI, XXXVII. 10 R. Docs. 30, 33, and 35. 11 See, e.g., Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007); Cuvillier v. Taylor, 503 F.3d 397, 401 (5th Cir. 2007). 12 Gonzalez v. Kay, 577 F.3d 600, 603 (5th Cir. 2009) (quoting Twombly, 550 U.S. at 555). 13 Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (quoting Twombly, 550 U.S. at 570). 14 Id. 15 Lormand v. U.S. Unwired, Inc., 565 F.3d 228, 239 (5th Cir. 2009). 16 Iqbal, 556 U.S. at 678. 12(b)(6) are viewed with disfavor and are rarely granted.”17 As a result, the Court should generally “afford plaintiffs at least one opportunity to cure pleading deficiencies before dismissing a case, unless it is clear that the defects are incurable or the plaintiffs advise the court that they are unwilling or unable to amend in a manner that will avoid dismissal.”18

II. Motion to Dismiss Under Rule 9(b) Federal Rule of Civil Procedure 9(b) governs pleading standards for fraud claims, including state-law fraud claims.19 Rule 9(b) also applies to negligent misrepresentation claims “when based on the same alleged facts as a fraud claim.”20 Rule 9(b) provides: “In alleging fraud or mistake, a party must state with particularity the circumstances constituting fraud or mistake.”21 “What constitutes ‘particularity’ will necessarily differ with the facts of each case and hence the Fifth Circuit has never articulated the requirements of Rule 9(b) in great detail.” 22 The Fifth Circuit “interprets Rule 9(b) strictly, requiring the plaintiff to specify the statements contended to be fraudulent, identify the speaker, state when and where the statements were made, and explain why the statements were fraudulent.”23 “At a minimum, Rule 9(b) requires allegations of the

particulars of time, place, and contents of the false representations, as well as the identity of the person making the misrepresentation and what he obtained thereby.”24 A plaintiff’s

17 Lormand, 565 F.3d at 232 (5th Cir.2009) (citation omitted). 18 Great Plains Trust Co. v. Morgan Stanley Dean Witter & Co., 313 F.3d 305, 329 (5th Cir. 2002). 19 Dorsey v. Portfolio Equities, Inc., 540 F.3d 333, 338–39 (5th Cir. 2008) (“[S]tate-law fraud claims are subject to the pleading requirements of Rule 9(b).”) (citing Abrams v. Baker Hughes Inc., 292 F.3d 424, 430 (5th Cir. 2002); Williams v. WMX Technologies, Inc., 112 F.3d 175, 177 (5th Cir. 1997)). 20 Center for Reconstructive Breast Surgery, LLC v. Blue Cross Blue Shield of La., No. 11–806, 2014 WL 4930443, at *7 (E.D. La. Sept. 30, 2014) (citing Benchmark Elecs., Inc. v. J.M. Huber Corp., 343 F.3d 719, 723 (5th Cir. 2003)). 21 Fed. R. Civ. P. 9(b). 22 Guidry v. Bank of LaPlace, 954 F.2d 278, 288 (5th Cir. 1992). 23 Flaherty & Crumrine Preferred Income Fund, Inc. v. TXU Corp., 565 F.3d 200, 207 (5th Cir. 2009). 24 Tel–Phonic Services, Inc. v. TBS Int'l, Inc., 975 F.2d 1134, 1139 (5th Cir. 1992). failure to meet Rule 9(b)’s heightened pleading requirements “should not automatically or inflexibly result in dismissal of the complaint,” but rather a plaintiff should be granted leave to amend unless amendment would be futile or the plaintiff has already been granted opportunities to amend.25 LAW AND ANALYSIS

I. The LPLA The LPLA “establishes the exclusive theories of liability for manufacturers for damage caused by their products.”26 The four theories under which a plaintiff may recover in an LPLA action are that the product in question was unreasonably dangerous: (1) in construction or composition27; (2) in design28; (3) because of inadequate warning29; or (4) because of nonconformity to an express warranty.30 A few applicable limitations on the exclusivity provision of the LPLA warrant brief discussion. First, the LPLA applies only to manufacturers.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Williams v. WMX Technologies, Inc.
112 F.3d 175 (Fifth Circuit, 1997)
Abrams v. Baker Hughes Inc.
292 F.3d 424 (Fifth Circuit, 2002)
Cuvillier v. Taylor
503 F.3d 397 (Fifth Circuit, 2007)
Dorsey v. Portfolio Equities, Inc.
540 F.3d 333 (Fifth Circuit, 2008)
Lormand v. US Unwired, Inc.
565 F.3d 228 (Fifth Circuit, 2009)
Gonzalez v. Kay
577 F.3d 600 (Fifth Circuit, 2009)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Cates v. International Telephone And Telegraph Corp.
756 F.2d 1161 (Fifth Circuit, 1985)
Robert J. Guidry v. Bank of Laplace, Etc.
954 F.2d 278 (Fifth Circuit, 1992)
Adams v. Owens-Corning Fiberglas Corp.
923 So. 2d 118 (Louisiana Court of Appeal, 2005)
Benchmark Electronics, Inc. v. J.M. Huber Corp.
343 F.3d 719 (Fifth Circuit, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
Gomilla v. Bracco Diagnostics, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/gomilla-v-bracco-diagnostics-inc-laed-2019.